UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
Manhattan Pharmaceuticals, Inc.
(f/k/a Atlantic Technology Ventures, Inc.)
Common Stock, par value $.001 per share
(Title of Class of Securities)
April 7, 2003
(CUSIP Number: 563 118 108)
Date of event which requires filing
February 21, 2003
Check the appropriate box to designate the rule pursuant to which the schedule
is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be filled for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act,
but shall be subject to all other provisions of the Act (however, see the Notes
to Schedule 13G).
1
---------------------------------------------------------------------------------------------------------------------------------
CUSIP No. 563 118 108 13G
---------------------------------------------------------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Lindsay A. Rosenwald, M.D.
---------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)
---------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
---------------------------------------------------------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
---------------------------------------------------------------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY 5 SOLE VOTING POWER
EACH REPORTING PERSON WITH
11,468,199
-----------------------------------------------------------------------------------
6 SHARED VOTING POWER
None
-----------------------------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
11,468,199
-----------------------------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
None
---------------------------------------------------------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11,468,199
---------------------------------------------------------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES*
---------------------------------------------------------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.8%
---------------------------------------------------------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
---------------------------------------------------------------------------------------------------------------------------------
2
Manhattan Pharmaceuticals, Inc. (f/k/a Atlantic Technology Ventures, Inc.)
(the "Company")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
787 Seventh Avenue, 48th Floor
New York, NY 10019
ITEM 2(a) NAME OF PERSON FILING:
Lindsay A. Rosenwald
ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
787 Seventh Avenue, 48th Floor
New York, NY 10019
ITEM 2(c). CITIZENSHIP:
United States
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, $0.001 par value.
ITEM 2(e). CUSIP NUMBER: 563 118 108
ITEM 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C.
78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.
78c).
(d) [ ] Investment company registered under section 8 of the Investment Company
Act of 1940 (15 U.S.C 80a-8).
(e) [ ] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
ss.240.13d-1(b)(1)(ii)(F);
3
(g) [ ] A parent holding company or control person in accordance with ss.
240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
(h) [X] Not Applicable
ITEM 4. OWNERSHIP
Pursuant to the merger (the "Merger") of Manhattan Pharmaceuticals,
Inc. ("Manhattan") and Atlantic Technology Ventures, Inc.
("Atlantic"), Atlantic issued 12.709 of its shares of Common Stock to
Manhattan stockholders. Dr. Rosenwald, who was also a substantial
stockholder of Atlantic, was issued 7,975,322 shares of Common Stock.
In addition, in connection with the Merger, holders of certain Common
Stock Warrants of Atlantic exchanged such warrants for shares of
Common Stock on the basis of one share of Common Stock for every three
shares of Common Stock underlying the Warrants. As a result of such
exchange, Dr. Rosenwald was issued 694,444 shares of Common Stock. In
addition, Dr. Rosenwald holds 3,122,665 shares of Common Stock and
warrants to purchase 370,212 shares of Common Stock of the Issuer.
Accordingly, Dr. Rosenwald may be deemed to beneficially own
11,468,199 shares of Common Stock or 9.8% of the Issuer.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in a transaction
having that purpose and effect.
4
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: April 7, 2003 By: /s/ Lindsay A. Rosenwald
New York, NY -------------------------------------------
Name: Lindsay A. Rosenwald, M.D.
5